The First Hospital of Jilin University
Changchun, Jilin, 130021, China
NCT Number: NCT04232514
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of HEC74647 combined with HEC110114 in healthy subjects
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Changchun, Jilin, 130021, China
This is a 2-part study with each part is an open-label study in healthy adult subjects.
Total 28 subjects will be enrolled into the study and divided into 2 part (Part A and Part B), 14 subjects in each part. With each part, the subject will be receive study drug per the defined treatment periods of Day 1~7 and Day 13~19.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered HEC74647 200 mg orally once daily in fed state
Administered HEC110114 800 mg orally once daily in fed state
Time frame: From Days 1-26
Incidence of adverse events
Time frame: Day 7-12 and Day 19-26
Maximum plasma concentration of study drugs
Time frame: Day 7-12 and Day 19-26
Maximum plasma concentration of study drugs
Sunshine Lake Pharma Co., Ltd.
Industry
A Open-label, Single Center Drug Interaction Study Between HEC74647PA Capsule and HEC110114 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01010646
Blood-Borne Infections, Chronic Disease
Lyon, France
View Trial DetailsNCT01226446
Blood-Borne Infections, Chronic Disease
Paris, France
View Trial DetailsNCT00200343
Blood-Borne Infections, Chronic Disease
Hongo, Bunkyo-ku, Tokyo, Japan
View Trial DetailsNCT01466192
Blood-Borne Infections, Chronic Disease
Minato-ku, Tokyo, Japan
View Trial Details